Necrotising cutaneous lesions as a side effect of glatiramer acetate [6]

Journal of Neurology

Volumn 253, Issue 10, 2006, Pages 1370-1371

  Bosca, Isabel ^a   Bosca, Maria ^a   Belenguer, Antonio ^b   Evole, Monserrat ^a   Hernandez, Miguel ^a   Casanova, Bonaventura ^a   Coret, Francisco ^c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; GLATIRAMER; INTERFERON;

ADULT; BLISTER; CASE REPORT; DRUG ERUPTION; DRUG INDICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GANGRENE; HUMAN; HUMAN TISSUE; INJECTION SITE ERYTHEMA; INJECTION SITE NECROSIS; LETTER; LIVEDO RETICULARIS; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT OUTCOME;

ADULT; DRUG ERUPTIONS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NECROSIS; PEPTIDES; SKIN;

EID: 33750615091     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0233-9     Document Type: Letter

References (10)

1. Albrecht KH, Littmann K, Richter HJ, Eigler FW (1984) Animal experiment studies of embolia cutis medicamentosa. Langenbecks Arch Chir 362(1):17-23
2. Edgar CM, Brunet DG, Fenton P, et al. (2004) Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 31(1):58-63
3. Gaudez C, Regnier S, Aractingi S, Heinzlef O (2003 May) Livedo-like dermatitis (Nicolau's syndrome) after injection of Copolymer-1(Glatiramer acetate) Rev Neurol (Paris). 159(5 Pt 1):571-3
4. Johnson KP, Brooks BR, Cohen JA, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: result of a phase III multicentre, double-blind, placebo-controlled trial. Neurology 45:1268-1276
5. Johnson KP, Brooks BR, Cohen JA, et al. (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701-708
6. Johnson KP, Brooks BR, Ford CC, et al. (2000) and the Copolymer 1 Multiple Sclerosis Study Group. Sustained Clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 6:255-66
7. Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, Ratto S (2000 Mar) Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol 247(3):220-1
8. Radziwill A, Courvoisier S (1999) Severe necrositing cutaneous lesions complicating treatment with interferon β-1a. J Neurol Neurosurg Psychiatry 67(1):115
9. Sheremata WA, Taylor JR, Elgart GW (1995) Severe necrotising cutaneous lesions complicating treatment with interferon beta 1-b. N Engl J Med 332:1584
10. Soos N, Shakery K, Mrowietz U (2004) Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol 5(5):357-9